In this study from the Journal of Clinical Oncology, the authors attempted to characterize the cancer-associated risk factors for COVID-19 adverse outcomes. Their hypothesis was that cytotoxic chemotherapy administered within 35 days of a COVID-19 diagnosis is associated with an increased hazard ratio (HR) of severe or critical COVID-19. Were they right?